Learn about the Trial to Assess Chelation Therapy 2 (TACT2) in this free presentation from the study chairman, Dr. Gervasio Lamas. Audio included.
Chelation therapy has long been scorned by many in the medical community. But after a major study suggested it was somewhat effective for heart disease, the alternative health treatment is once again going under the microscope. A second study called TACT 2 (Trial to Assess Chelation Therapy) will assess chelation’s heart-health benefits for patients with diabetes.
Lead exposure may be responsible for nearly 10 times more deaths in the United States than previously thought, according to a new study from The Lancet Public Health.
Dr. Jeff Baker, of Clinical Research Prime in Idaho Falls, Idaho, explains how removing toxic metals from the body with chelation therapy could help patients with cardiovascular issues. His clinic is a participating site for TACT2.
TACT2 investigator Dr. Richard Nahas will present a free information session on diabetes, heart disease, and the TACT2 study on Tuesday, February 13, 7:00–8:30 p.m., at Ben Franklin Place in Ottawa, ON. RSVP required. Contact 613.727.7246 or email@example.com for more information.
Listen to Dr. Nahas talk about the history, goals, and significance of TACT2 in the video below.
Los diabéticos Tipo 2 con historial de paro cardíaco pueden encontrar una solución a sus complicaciones. ¿La clave? Una droga desarrollada en la década de 1950.
Type 2 diabetics with a history of cardiac arrest might find a solution to their complications. The key? A drug developed in the 1950s.
Tact2 investigator Dr. Gervasio Lamas explains how chelation therapy could be a “game changer” in the treatment and prevention of heart disease.
March 28, 2017
Little Rock, Arkansas: The Arkansas Heart Hospital is now involved in a clinical trial that could lead to a new way to treat heart disease. Jancey Sheets has more on Chelation Therapy in today’s heartbeat segment on Fox16.com.
March 20, 2017
MARQUETTE, Mich. (WLUC) – An area doctor, right in Marquette, is part of a multinational therapy trial. This is the second stage of the trial to assess chelation therapy. The trial is a 40-week intravenous therapy that removes heavy metals from patients.